Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Jae Hee Cho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4174-0091; OpenAlex author ID A5022753022. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 5 papers · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 19

  1. Disulfiram/Copper Complex Induces Cytotoxicity in Pancreatic Cancer Cells and 5-Fluorouracil-Resistant Cells through Nuclear Factor E2-Related Factor-2 Suppres… Last author DOI 10.5009/gnl250028↗
  2. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  3. A New Staining Method Using Methionyl-tRNA Synthetase 1 Antibody for Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics15141783↗
  4. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  5. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-… Co-author DOI 10.1007/s00262-023-03458-8↗
  6. Annotation-Efficient Deep Learning Model for Pancreatic Cancer Diagnosis and Classification Using CT Images: A Retrospective Diagnostic Study. Co-author DOI 10.3390/cancers15133392↗
  7. Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining. Co-author DOI 10.3390/cancers15225413↗
  8. Prognostic Impact of Minimal Pelvic Fluid in Locally Advanced Pancreatic Cancer: A Multicenter Retrospective Study. Co-author DOI 10.5152/tjg.2023.23309↗
  9. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Last author DOI 10.3390/cancers14010236↗
  10. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers14030853↗
  11. Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed … Co-author DOI 10.5009/gnl210123↗
  12. Corrigendum: Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate… Co-author DOI 10.5009/gnl210123.e↗
  13. The role of Jagged1 as a dynamic switch of cancer cell plasticity in PDAC assembloids. Co-author DOI 10.7150/thno.71364↗
  14. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  15. NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression. Last author DOI 10.3390/ijms21134646↗
  16. Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the form… Co-author DOI 10.18632/oncotarget.19458↗
  17. Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer stem cell formation by reducing the levels of peroxiredoxin II and reactive oxygen… Last author DOI 10.3892/or.2017.6045↗
  18. Successful hemostasis using a covered self-expandable metallic stent for spurting hemobilia in patients with advanced pancreatic cancer-induced portal biliopat… First author DOI 10.1016/j.gie.2016.05.042↗
  19. [Recent update of molecular targeted therapy in pancreatic cancer]. Co-author DOI 10.4166/kjg.2013.61.3.147↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sung Ill Jang · 10 shared papers, 2022–2026 · strength 1.92
  2. Jung Hyun Jo · 5 shared papers, 2022–2026 · strength 1.09
  3. Dong Ki Lee · 4 shared papers, 2022–2025 · strength 0.71
  4. Hee Seung Lee · 3 shared papers, 2022–2025 · strength 0.53
  5. Moon Jae Chung · 3 shared papers, 2022–2025 · strength 0.53
  6. Jeong Youp Park · 3 shared papers, 2022–2025 · strength 0.53
  7. Seungmin Bang · 3 shared papers, 2022–2025 · strength 0.53
  8. Joon Seong Park · 3 shared papers, 2022–2023 · strength 0.49
  9. Seong‐Hun Kim · 3 shared papers, 2022–2023 · strength 0.44
  10. Jiyoung Keum · 2 shared papers, 2024–2025 · strength 0.38
  11. Kyung In Shin · 2 shared papers, 2024–2025 · strength 0.38
  12. Eun Kyoung Kim · 1 shared paper, 2026 · strength 0.33
  13. Seung Woo Park · 2 shared papers, 2022–2024 · strength 0.33
  14. Hyung Keun Lee · 2 shared papers, 2022–2023 · strength 0.32
  15. Eui Joo Kim · 3 shared papers, 2016–2020 · strength 0.30
  16. Woo Jin Lee · 2 shared papers, 2021–2023 · strength 0.29
  17. Sang Myung Woo · 2 shared papers, 2021–2023 · strength 0.29
  18. Tae Jun Song · 2 shared papers, 2022 · strength 0.26
  19. Jun‐Ho Choi · 2 shared papers, 2022 · strength 0.26
  20. Sung Woo Ko · 2 shared papers, 2022 · strength 0.26
  21. Sang Hyub Lee · 2 shared papers, 2022 · strength 0.26
  22. Jai Hoon Yoon · 2 shared papers, 2022 · strength 0.26
  23. Seung Bae Yoon · 2 shared papers, 2022 · strength 0.26
  24. Dong‐Wan Seo · 2 shared papers, 2022 · strength 0.26
  25. Hoon Jai Chun · 2 shared papers, 2022 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.